Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Axitinib × Lymphoid × Clear all

Status

Sponsor Class

NETWORK 1 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 31 Thoracic 9 Gastrointestinal 9 Tumor-Agnostic 6 Other solid neoplasm 4 Gynecologic 3 Head & Neck 2 Dermatologic 2 Sarcoma 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 CNS 1 Breast 1

Conditions

Lymphoma, Mantle-Cell 1 Carcinoma 1

Interventions

Rituximab 374 Cyclophosphamide 178 Bendamustine Hydrochloride 108 obinutuzumab 100 Vincristine 94 fludarabine 91 ibrutinib 89 Prednisone 89 Doxorubicin 89 venetoclax 85 Lenalidomide 81 Gemcitabine 64 acalabrutinib 48 Brentuximab Vedotin 44 pembrolizumab 42 zanubrutinib 41 Dexamethasone 40 idelalisib 37 ofatumumab 32 Oxaliplatin 29 Chlorambucil 29 polatuzumab vedotin 24 blinatumomab 24 Azacitidine 24 tocilizumab 23 tositumomab I-131 22 Prednisolone 22 tisagenlecleucel 21 glofitamab 21 Nivolumab 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00700258 2024-09-23

STAR-TOR

Pfizer

1,520 enrolled 24 charts

Carcinoma, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡